Your browser does not support JavaScript!
:::
:::
鄭恩加教授
 

鄭 恩 加 (Ann-Joy Cheng)

學歷

美國德州大學安德生癌症中心腫瘤生物學博士

任課科目

臨床化學、分子生物學、細胞生物學、醫用生物技術學、生技學研究實驗

研究專長

腫瘤生物學、.細胞分子生物學、生物化學 、醫學生物技術

辦公室分機

5085

實驗室分機

5216

個人網頁

轉譯癌症研究室

E-mail

annjoycheng@gap.cgu.edu.tw

研究方向及研究室特色(Lab & Research Interest)

       我們轉譯癌症實驗室以研究臨床相關的癌症議題為主,並且致力於本土頭頸癌之研究。頭頸癌包含口腔癌、咽喉癌,是個本土性高的惡性疾病。在台灣,頭頸癌是十大癌症之一,是近十年來有好發率攀升最高之癌症,且因頭頸癌好發在中年男性,因此對家庭及社會無形中造成相當大的影響,因此,對頭頸癌致癌因子研究之急切性,可說是刻不容緩。以流行病學的角度看,西方國家的頭頸癌占所有惡性腫瘤約3%,台灣占約10%,而好發最高的印度占約30%,這些差異,除了族群基因體本身的因素外,可能與所接觸的致癌因子以關,如,印度地區常嚼食雪茄及成熟檳榔,台灣病患常是煙、酒、青檳榔合併習慣性使用,而西方國家並無嚼食檳榔的習慣。因為流行病學、致癌因子及臨床表徵上的差異極大,台灣頭頸癌之致癌機轉也可能有其區域獨特性,因此本土的頭頸癌必須自己來研究並解決。

       頭頸癌依各部位與個別狀況,在臨床治療上,常結合手術與放射或化學治療,各專科醫師相互配合並分行其職,而我們實驗室與臨床醫師們共同組成長庚頭頸癌研究團隊,進行臨床相關的議題研究,研究內容含致癌因子機制、癌症標誌研發、癌症分子病理機轉,到治療預後評估,如癌細胞侵犯轉移、放化療抵抗性等。為達成這些目標,我們建立了數株本土頭頸癌細胞株,並高侵犯性細胞子株、抗放射子株、抗化藥子株、慢性檳榔暴露子株等,並運用基因蛋白質體學等方法,全面性探討導致這些細胞表徵的基因轉譯圖誌,再以生物資訊和細胞動物模式,探討分子間的網絡途徑和基因功能,並進行臨床相關性分析,以期系統性探討頭頸癌癌化之分子機制。目前我們已發現數個分子,首先報導與頭頸癌相關,如DSG3、Grp78、Gp96等,分別調控細胞侵犯轉移、調控癌幹細胞形成、或扮演抗放化療的角色等。未來,期望這些結果不只在癌症醫學知識有所貢獻,更能研發出有效輔助診治頭頸癌之工具,供臨床使用,使頭頸癌得以控制,增進台灣及國際社會的健康福祉。

論文與著作(Publication)

A. 論文

  1. Chen YJ, Kuo CC, Ting LL, Lu LS, Lu YC, Cheng AJ, Lin YT, Chen CH, Tsai JT, Chiou JF. (2018, Feb). Piperlongumine inhibits cancer stem cell propertiesand regulates multiple malignant phenotypes in oral cancer. Oncol Lett, 15(2):1789-1798. (SCI, 88.47% , 192/217 Oncology).
  2. Chen HY, Chang TC, Chien KY, Lee YS, You GR, Cheng AJ*. (2018, Jan). The endogenous Grp78 interactome in human head and neck cancers: a deterministic role of cell surface Grp78 in cancer stemness. Sci Rep , 8(1): 536. (SCI, 15.63% ,10/64 Multidisciplinary Sciences). 本人為通訊作者.
  3. Tsai CY, Chi HC, Chi LM, Yang HY, Tsai MM, Lee KF, Huang HW, Chou LF, Cheng AJ, Yang CW, Wang CS, Lin KH. (2018, Jan). Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy. FASEB J. (SCI, 8.23% , 7/85 Biology).
  4. Lu YC, Cheng AJ#, Lee LY, You GR, Li YL, Chen HY, Chang JT. (2017, May). MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44. Sci Rep., 7 (1): 2042.. (SCI, 15.63% , 10/64 Multidisciplinary sciences). NSC 103-2314-B-182A-011-MY3. 本人為第一作者.
  5. Yan-Liang Li, Joseph T. Chang, Li-Yu Lee, Kang-Hsing Fan, Ya-Ching Lu,Yi-Chen Li, Chang-Hsu Chiang, Guo-Rung You, Hsin-Ying Chen, Ann-Joy Cheng*. (2017, Jan). GDF15 contributes to radioresistance and cancer stemness of head and neck cancer by regulating cellular reactive oxygen species via a SMADassociated signaling pathway. Oncotarget, 8 (1): 1508-1528. . (SCI, 20.28% , 44/217 Oncology). MOST 101-2314-B-182A-121-MY3. 本人為通訊作者.
  6. Chiang CH, Wu CC, Lee LY, Li YC, Liu HP, Hsu CW, Lu YC, Chang JT, Cheng AJ*. (2016, Sep). Proteomics analysis reveals involvement of Krt17 in areca nut – induced oral carcinogenesis. J Proteome Res, 15: 2981-2997. (SCI, 15.58% ,12/77 Biochemical Research Methods). MOST 101-2314-B-182A-121-MY3. 本人為通訊作者.
  7. Chao YK, Peng TL, Chuang WY, Yeh CJ, Li YL, Lu YC, Cheng AJ*. (2016, Jul). Transketolas serve a poor prognosticator in esophageal cancer by promoting cell invasion via epithelial– mesenchymal transition. J Cancer, 7: 1408-1811. (SCI, 34.27% , 73/213 Oncology). 本人為通訊作者.
  8. Cheng CW, Hsiao JR, Fan CC, Lo YK, Tzen CY, Wu LW, Fang WY, Cheng AJ, Chen CH, Chang IS, Jiang SS, Chang JY, Lee AY. (2016, May). Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial- mesenchymal transition in oral squamous cell carcinoma. Mol Carcinog, 55(5): 499-513.. (SCI, 19.71% , 42/213 Biochemistry & Molecular Blology).
  9. Li YC, Chang JT, Chiu C, Lu YC, Yi YL, Chiang CH, You GR, Lee LY, Cheng AJ*. (2016, May). Areca nut contributes to oral malignancy through facilitating the conversion of cancer stem cells. Mol Carcinog, 6: 25188-25201.. (SCI, 19.71% , 42/213 Biochemistry & Molecular Biology). 本人為通訊作者.
  10. Lu YC, Chang JT, Chan EC, Chao YK, Yeh TS, Chen JS, Cheng AJ*. (2016, Mar). miR-196, an emerging cancer biomarker for digestive tract cancers. J Cancer, 7(6): 650-655. (SCI, 34.27% , 73/213 Oncology). MOST 103-2314-B-182A-011-MY3. 本人為通訊作者.
  11. Martel J, Wu CY, Hung CY, Wong TY, Cheng AJ, Cheng ML, Shiao MS, Young JD. (2016, Mar). Fatty acids and small organic compounds bind to mineraloorganic nanoparticles derived from human body fluids as revealed by metabolomic analysis. Nanoscale, 8(10): 5537-5545. (SCI, 8.48% , 23/271 Chemisrty , Multidisciplinary).
  12. Lee CH, Pank KL, Tang YC, Tsai MH, Cheng AJ, Shen MY, Cheng YM, Huang TT, Lin P. (2015, Sep). LDOC1 silenced by cigarette exposure and involved in oral neoplastic transformation. Oncotarget, 6: 25188-25201. (SCI, 20.28% ,44/217 Oncology).
  13. Lee LY, Chen YJ, Lu YC, Liao CT, Chen IH, Chang JTC, Huang YC, Chen WH, Huang CC, Tsai CY, Cheng AJ*. (2015, Sep). Fascin is a circulating tumor marker for head and neck cancer as determined by a proteomic analysis of interstitial fluid from the tumor microenvironment. Clin Chem Lab Med, 53:1061-1641. (SCI, 16.67% , 5/30 Medical Laboratory Technology). 本人為通訊作者.
  14. Lu YC, Chang JT, Huang YC, Huang CC, Chen WH, Lee LY, Huang BS, Chen YJ, Li HS, Cheng AJ*. (2015, Feb). Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clin Biochem, 48: 115-121. . (SCI, 36.67% , 11/30 Medical Laboratory Technology). 本人為通訊作者.
  15. Lu YC, Chang JT, Liao CT, Kang CJ, Huang SF, Chen IH, Huang CC, Huang YC, Chen WH, Tsai CY, Wang HM, Yen TC, You GR, Chiang CH, *Cheng AJ. (2014, Sep). OncomiR-196 promotes an invasive phenotype in oral cancer through the NEM4-JNK-TIMP1-MMP signaling pathway . Molecular Cancer, 13: 218.. (SCI, 12.41% , 36/290 Biochemistry & Molecular Biology). 本人為通訊作者.
  16. Peng SC, Liao CT, Peng CH, Cheng AJ, Chen SJ, Huang CG, Hsieh WP, Yen TC. (2014, Jul). MicroRNA miR-218, mir-125b, and let-7g predict prognosis in patients with oral cavity squamous cell carcinoma . PLoS One , 9: e102403..(SCI, 23.44% , 15/64 Multidisciplinary Sciences).
  17. Lu YC, Cheng AJ*. (2014, May). Pathological function and clinical significance of microRNA-10b in cancer. Cancer Sci Res Open Assess , 1(2): 1-5. 本人為通訊作者.
  18. Huang WC, Chan SH, Jang TH, Chang JW, Ko YC, Yen TC, Chiang SL, Chiang WF, Shieh TY, Liao CT, Juang JL, Wang HC, Cheng AJ, Lu YC, Wang LH.(2014, Feb). miRNA-491-5p and GIT1 Serve as Modulators and Biomarkers for Oral Squamous Cell Carcinoma Invasion and Metastasis . Cancer Res., 74(3):751-64. . (SCI, 6.91% , 15/217 Oncology).
  19. Yen YC, Shiah SG, Chu HC, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, Cheng AJ, Lu YC, Chen YW. (2014, Jan). Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells. Mol Cancer., 13:6.. (SCI, 12.41% , 36/290 Biochemistry & Molecular Biology).
  20. Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li YL, Wang HM, Chang JTC, Cheng AJ*. (2013, Nov). Grp78 as a therapeutic target for refractory head-neck cancer with CD24-CD44+ stemness phenotype . Cancer Gene Ther, 20: 606-615.. (SCI, 25% , 40/160 Biotechnology & Applied Microblology). 本人為通訊作者.
  21. Lee CH, Wong TS, Chan JY, Lu SC, Lin P, Cheng AJ, Chen YJ, Chang JS, Hsiao SH, Leu YW, Li CI, Hsiao JR, Chang JY. (2013, Jul). Epigenetic regulation of the X-linked tumor suppressors BEX1 and LDOC1 in oral squamous cell carcinoma . J Pathol, 230: 298-309.. (SCI, 10.13% , 22/217 Oncology). NSC 99-2320-B-400-014.
  22. Jian SL, Hsieh HY, Liao CT, Yen TC, Nien SW, Cheng AJ, Juang JL. (2013,Jun). Ga12 drives invasion of oral squamous cell carcinoma through upregulation of proinflammatory cytokines. PLoS One, 8: e66133.. (SCI, 23.44% ,15/64 Multidisciplinary Sciences ).
  23. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, et al. (2013, Jun). Identification of targetable EGFR gene fusions in diverse cancers. Cancer Discov, 3:636-647.. (SCI, 3.23% ,7/217 Oncology).
  24. Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC, Li HF, Chiu CC, Li YL, Chiou JF, Cheng AJ*. (2013, May). DSG3 facilitates cancer cell growth and invasion through the DSG3- plakoglobin - TCF/LEF - myc / cyclinD1 / MMP signaling pathway. PLoS One, 8:e60488.. (SCI, 23.44% , 15/64 Multidisciplinary Sciences ). 本人為通訊作者.
  25. Le QT, Zhang Q, Cao H, Cheng AJ, Pinsky BA, Hong RL, Chang JT, Wang CW, Tsao KC, Lo YD, Lee NY, Ang KK, Chan AT, Chan KA. (2013, Apr). AnInternational Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus (EBV) DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. Clin Cancer Res, 19: 2208-2015.. (SCI, 5.53% , 12/217 Oncology

*Corresponding author

B.  書籍/書籍章節

  1. 醫學分子檢驗,第13蛋白質體學及腫瘤胞至蛋白的研發。(陳盈汝、鄭恩加)五南出版社。2009第一版。

  1. 臨床化學原理、步驟與關連性。合計圖書出版社。(編輯:趙啟淵。監修魏正舒、鄭恩加、沈武訓、顏秀娟)。合計圖書出版社。2003第一版。

  2. 通識版生物技術,第5生物技術在臨床診斷上之應用。中華民國教育部發行。(趙崇義、鄭恩加)1998第一版。

C.   專利

  1. Cheng AJ, Chiu CC, Chang JT. Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof - a method for head and neck cancer. United States Patent. (Patent #: US 7,825,100 B2) ( Patent date: Nov 2, 2010)

  1. Cheng AJ, Chiu CC, Chang JT. Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof - specific Grp78-RNAi sequence. United States Patent. (Patent #: US 7,829,695 B2) ( Patent date: Nov 9, 2010)

  2. Cheng AJ, Chen YJ, Chang JT. Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression – a suppression method. United States Patent. (Patent #: US 7,622,456 B2) ( Patent date: Nov 24, 2009)

  3. Cheng AJ, Chen YJ, Chang JT. Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression – a suppression reagent. United States Patent. (Patent #: US 7,622,456 B2) ( Patent date: June 8, 2010)

  4. 鄭恩加、張東杰、邱清旗。專一性抑制葡萄糖調節蛋白-78(Grp78)表現之RNA干擾(RNAi)序列、抑制藥劑及抑制方法。中華民國專利。專利案號: I-371285,核准日期: 201291日,專利權期: 201291日至2028110日。

  5. 鄭恩加、陳盈汝、張東杰。DSG3 分子於頭頸癌之臨床應用-預測癌症惡性程度及作為分子應用標的的方法與專一性抑制DSG3表現之RNA干擾序列運用方法。中華民國專利。(專利案號: 095140849,核准日期: 2012913)

類別

專利名稱

國別

專利號碼

發明人

專利權人

專利核准

    

國科會

計畫編號

(A)發明專利

Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression _ a suppression method.

美國

US 7,622,456 B2

鄭恩加等

長庚大學

長庚醫院

Nov 24, 2009

NSC- 91-2314-B-182-058

NSC-92-2314-B-182-058

NSC-93-2314-B-182-058

(A)發明專利

Methods on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degrees of cancer, serving as a molecular target and using RNA jamming sequence on inhibition- specific of DSG3 expression _ a suppression reagent.

美國

US 7,732,594 B2

鄭恩加等

長庚大學

長庚醫院

Jun 8, 2010

NSC- 91-2314-B-182-058

NSC-92-2314-B-182-058

NSC-93-2314-B-182-058

(A)發明專利

Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof _  a method for head and neck cancer

美國

US 7,825,100

B2

鄭恩加等

長庚大學

Nov 2, 2010

NSC-94-2320-B-182-042

NSC-94-2745-B-182-004-URD

NSC-95-2745-B-182-004-URD

(A)發明專利

Specific Grp78 expression- inhibition RNAi sequence, medicine thereof and method thereof _ specific Grp78-RNAi sequence.

美國

US 7,829,695 B2

鄭恩加等

長庚大學

Nov 9, 2010

NSC-94-2320-B-182-042

NSC-94-2745-B-182-004-URD

NSC-95-2745-B-182-004-URD

(A)發明專利

專一性抑制葡萄糖調節蛋白78(Grp78)  表現之RNA干擾(RNAi)序列、抑制藥劑及抑制方法

中華民國

I-371285

鄭恩加等

長庚大學

Sep 1, 2012

(2012.09.01~

2028.01.10)

NSC-94-2320-B-182-042

NSC-94-2745-B-182-004-URD

NSC-95-2745-B-182-004-URD

(A)發明專利

DSG3 分子於頭頸癌之臨床應用-預測癌症惡性程度及作為分子應用標的的方法與專一性抑制 DSG3表現之RNA干擾序列運用方法

中華民國

95140849

鄭恩加等

長庚大學

長庚醫院

Sep 13, 2012

NSC- 91-2314-B-182-058

NSC-92-2314-B-182-058

NSC-93-2314-B-182-058

 

瀏覽數  
  • 友善列印
  • 新增到收藏夾
  • 分享
將此文章推薦給親友
請輸入此驗證碼
Voice Play
更換驗證碼